International Stem Cell (ISCO) 10-K2013 FY Annual report

Filed: 17 Mar 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abroad, accrual, assign, ATC, awardee, Beach, begun, bid, biopharmaceutical, Black, borne, Burnham, carryforward, chronological, civil, collateralize, contemplated, criminal, daytime, Deloitte, denied, disgorgement, dramatically, Duke, easier, Elan, EMD, envisioned, equitably, exceedingly, explicit, fall, FFDCA, FINRA, fraudulent, GMP, greatest, heightened, imposition, incentive, inconclusive, inInternal, interpreted, Jay, jeopardize, knowingly, lapsed, licensure, lieu, Lincoln, Medicare, MKT, multiplied, Nanogen, Neuralstem, NOL, nonclinical, Novak, NYSE, parent, Park, partner, passed, post, PromoCell, QSR, qui, rapidly, ratchet, reinterpretation, ReNeuron, restitution, retroactively, revolving, Roth, safer, Sanford, setback, show, solicitation, Stark, submission, successor, surveillance, susceptible, synthetic, tam, threshold, Tibor, Touche, trend, twelve, unavailable, unclear, undertaken, unexercised, unexpected, unused, Volcano, warning, whistleblower, withdrawal, Yale, York

Removed: Aastrom, addressed, advancement, age, ailing, announced, ASC, ATCC, back, bad, bear, Bermuda, Brian, cap, Centre, CG, characterizing, Chemicon, Chennai, China, Chinese, chronic, clause, cloned, cloning, commenced, compensate, confirm, contra, converting, corneally, customary, damaging, deal, deepened, Demonstrated, desired, diagnosed, Diego, distinct, distributed, distributing, dollar, Dolly, donated, drawdown, drawn, drew, Edinburgh, EITF, eliminating, embedded, enable, ensuring, ethnic, eventual, exciting, exempted, facing, Feasibility, filer, final, finalized, formula, formulating, frequency, fundamentally, genetically, Genzyme, Germany, GmbH, graft, great, half, harsh, healthy, hedging, hospital, Ian, illustrated, implantation, implanted, indemnify, integration, investigate, issuing, Japan, Jeanne, journal, junior, leader, liquidated, log, Loring, Lundstrom, Master, maturity, Mehra, modification, molecule, movement, MRC, Mueller, Narinder, Nethralaya, Network, neuronal, noticeably, Notwithstanding, ocular, OID, overcome, paper, peer, Perpetual, promissory, promptly, proportionate, reaction, recipient, redeem, redeemed, refusal, reimburse, renewable, repaid, repair, repayment, replacement, requirement, retired, San, Sankara, scarring, scientist, Secretary, secured, seller, seminal, settlement, Sharing, sheep, short, shortage, Singapore, Sir, step, Structural, structured, studying, sunscreen, supplemented, surgery, survive, Taiwan, terminated, thereof, thousand, Tranche, transplantable, trauma, twelfth, unqualified, unrealistic, vascularization, Vertrieb, Vital, waive, Walkersville, whatsoever, Wilmut, Wuerzburg

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ISCO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of International Stem Cell Corporation (the “Company”) on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission on March 17, 2014 (the “Report”), I, Jay Novak, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 17, 2014

/s/ JAYNOVAK

Jay Novak

Chief Financial Officer

(Principal Financial and Accounting Officer)